In order to help to clarify the mode of action of carnitine derivatives. plasma levels of adenosine. ATP and inosine were evaluated'ollowing the infusion of 0.75. 0.50 and 0.25 mg/kg/min propionyl-L-carnitine (PLC) for 30 min in patients affected with peripheral arterial disease. Moreover. the effects of 0.75 mg/kg/min acetyl-L-carnitine (ALC) and L-carnitine (LC) were studied in the same conditions. Finally. the activity of 7.5 mg/kg/min PLC administered for 3 min was also evaluated.
Introduction
Carnitine plays a crucial role in the shuttle mechanism of long-chain fatty acids from the cytosol to the mitochondria, whereby l3-oxidation of fatty acids occurs with energy production.':? Only the L-enantiomer form of carnitine is biologically active on those enzyme systems involved in the transport mechanism of fatty acids across the mitochondrial barrier.:':' The endogenous L-carnitine pool includes a series of short-, medium-and long-chain esters, I.2.5 among which acetyl-and propionyl-L-carnitine are the most extensively studied. All the L-carnitine esters are maintained in a homeostatic equilibrium. As a drug, carnitine, together with its derivatives, is employed in the treatment of primary carnitine deficiencies.v' Moreover, carnitine derivatives are employed in the treatment of those conditions, such as ischaemic syndromes, in which a secondary carnitine deficiency has been described."!" Evidence exists that carnitine derivatives protect muscle tissue towards ischaemia.":!' As local blood flow does not increase.':' the activity of the compounds is likely due to a cell metabolism affecting the mechanism of action. LC or PLC administration has beneficial effects on ischaemic and reperfused myocardium, 1 1-13 and it also improves walking capacity in patients affected with peripheral obliterative arterial disease.!" With respect to L-carnitine (LC) and acetyl-Lcarnitine (ALC), propionyl-L-carnitine (PLC) displays a greater affinity for carnitine-acetyltransferase," and a higher rate of transport into the heart and isolated cardiomyocytes.!"!" Thus, as concerns clinical effects, PLC has proved to be more effective than LC in protecting heart and peripheral skeletal muscles from ischaemia. I 1.14 ALC was also shown to induce acetylcholine-like activity in central nervous systern," thus suggesting the opportunity to employ this drug in the treatment of a series of disorders of the central and peripheral nervous system.l'"?"
Pharmacological activity of carnitine is commonly attributed to its biochemical properties of providing further substrates for energy expenditure in ischaemic tissues.">" However, the exact mechanism of action of the drug at the molecular level is still under investigation, Recent evidence has been provided that LC and PLC are able to increase the content of ATP and total adenine nucleotides inside different cell types, such as cardiomyocytes" and peripheral blood mononuclear cells." On the basis of such an activity of LC and PLC on the intracellular nucleotide pool, and in order to clarify further the mechanism of action of carnitine derivatives, plasma levels of adenosine and ATP were evaluated, together with the adenosine catabolic byproduct inosine, following the intravenous infusion of increasing doses of PLC, ALC and LC in humans.
Methods

Study design
Sixteen subjects affected with peripheral obliterative arterial disease at Fontaine's II stage (intermittent claudication) (10 males and six females, mean age 65.5 ::t 9.12 SD years), were studied after obtaining informed consent in accordance with the principles of the Declaration of Helsinki. PLC (Sigma-Tau, Pomezia, Italy) was administered as an intravenous infusion for 30 min in 100 ml saline. Blood withdrawals (3 ml) were performed from an antecubital vein of the arm not undergoing the infusion, at the S.N.K. were infused with 0.75 mg/kg/min LC (Sigma-Tau, Pomezia, Italy). Finally five subjects (three males and two females, mean age 65.3 ± 12.3 SO years) were treated with 100 ml saline containing the vehicle of 0.75 mg/kg/min PLC as a reference. Moreover, in order to better evaluate the dynamic profile of the effects of camitine derivatives, five subjects (four males and one female, mean age 56.3 ± 6.1 SO years), were treated with 7.5 mg/kg/min PLC in 10 ml saline, as a bolus administration for 3 min. Studies were repeated in the same subjects at a time interval of at least three days. Plasma levels of adenosine and ATP were measured at the following times: 0, 3 (end of bolus), 4, 5, 6, 8, 13, 18, 33 min.
Adenosine, ATP and inosine assay
Plasma levels of adenosine, ATP, and inosine were evaluated by high performance liquid chromatography (HPLC) on heparinized, ice preserved blood samples, treated with 50 j.LM dipyridamole (Boehringer Ingelheim, Germany) and Figure 2A) . Indeed, the increase in plasma levels of adenosine and ATP and the time-course of the phenomenon induced by ALC infusion were highly significant when evaluated with the Student-Neuman-Keuls's test and the ANOVA, respectively (Figure 2A ).
Statistical analysis
For each parameter, the comparison of peak and baseline values was performed by the Student-Neuman-Keuls's test for multiple measurements to evaluate the influence of the drug factor. One-way analysis of variance (ANOVA) was also performed to determine the effect of the time factor. The area under the curve was computed for each variable in the time interval 0-90 min by trapezoidal rule; the values obtained were subtracted from basal values multiplied by the time interval. These parameters were considered a measure of the average effect of the different treatments, thus allowing statistical evaluation of a possible dose dependency of the observed effects by Student-Neuman-Keuls's test. The same procedure was employed to compare the effects of 0.75 mg/kg/min PLC, ALe, and LC. Values of probability (P) less than 0.05 were considered significant.
Results
The infusion of 0.75, 0.50 and 0.25 mg/kg/min PLC intravenously for 30 min induced a statistically significant increase in plasma levels of adenosine ( Figure IA after PLC and LC administration, and 10 min after ALC administration (Figures 1 and 2) . Table 1 shows the behaviour of the adenosine/inosine ratio (ADO/INa ratio) in different conditions in the course of PLC, ALC and LC infusion. From the baseline values of 0.96, 0.92, and 0.93 for PLC, ALC, and LC, respectively, the ADO/INa ratio of the area under the curve of the infusion period of 30 min slightly increased (1.18, 1.16, and 1.11 for PLC, ALC and LC, respectively). However, such an increase was not statistically significant. The ADO/INa ratio of the area under the curve of the whole observation period of 90 min did not differ from that measured at baseline (0.99, 0.93 and 0.97 for PLC, ALC, and LC, respectively). Bolus administration of 7.5 mg/kg/min PLC for 3 min, produced a significant increase in plasma levels of adenosine and ATP (Figure 3 ). Peak plasma level of adenosine occurred I min after the end of PLC administration, whereas maximum increase in ATP levels occurred 2 min from the end of the bolus (Figure 3 ). In both cases baseline values were restored after 30 min recovery. The infusion of 0.75 mg/kg/min LC also produced significant changes in plasma levels of adenosine and ATP ( Figure 2B ), but such changes seemed less relevant than those observed with PLC and ALe. The area under the curve of the increase in adenosine, ATP and inosine plasma levels observed with PLC was not significantly different from that obtained with ALC when evaluated with the Student-Neuman-Keuls's test (6326.1 ± 2084.1, 3416.2 ± 1335.1,6390.0 ± 1916.2 vs 6257.5 ± 1301.8,3801.5 ± 1121.6, 6728.5 ± 1411.1 nmol/1/90 min, for adenosine, ATP, and inosine with PLC and ALC, respectively). Conversely, significance was observed for PLC-and ALCdependent changes with respect to LC-dependent modifications in plasma levels of adenosine, ATP and inosine (3657.5 ± 726.2 nmolll/90 min, p<O.OOI, 1414.0 ± 535.8, nmolll/90 min, p<O.OOI, 3770.6 ± 823.7 nmol/1/90 min, p<O.OOl).
Discussion
Interestingly, with PLC, ALC and LC peak plasma levels of adenosine were observed at the end of the infusion period, while peak time of ATP with respect to adenosine was delayed. Indeed, peak plasma levels of ATP occurred 5 min values high enough to be of physiological relevance.P">" In our study, the mode of action of the compounds is not directly elucidated. However, some indirect evidence seems to suggest enhancement of celI release rather than inhibition of celI uptake. The time course of the phenomenon is consistent with this interpretation: the adenosine plasma level reached its peak at the end of the infusion or the bolus with carnitine derivatives, and then progressively declined, in a fashion consistent with the rapid metabolic fate of the nucleoside (0.63-3.42 min).28-3o The nucleoside uptake inhibitor dipyridamole is reported to induce sustained levels of adenosine, with a prolongation of its half-life two-to fivefold." Furthermore, no significant changes in ADOIINO ratio are observed in our study, whereas treatment with nucleoside transport inhibitors markedly increases this ratio, at least in ischaemic conditions.v-?
The possibility that adenosine originates from extracelIular dephosphorilation of adenine nucleotides" would conflict with the observation that peak plasma levels of adenosine preceded those of ATP.
Since it has been demonstrated that celI release of ATP does not necessarily require loss of cell integrity;" the increase in plasma levels of ATP after PLC, ALC and LC administration could be an expression of the global ATP sparing effect of the compounds.P:" An increase in plasma levels of adenosine and adenine nucleotides, namely ATP, occurs during ischaemia, presumably because of an enhanced celI release.Y-" Adenosine and ATP plasma levels are dependent on the metabolic activity of endotheliai'v" and circulating cells, mainly erythrocytes" and platelets." and of myocytes.Pv'" The biologic significance of extracellular adenosine increase is related to its local vasodilating and tissue-protecting properties during ischaemia and inflammatory reactions. 24, 25, 36, 37, 41, 42 Moreover, adenosine regenerates the intracelIular adenine nucleotide pool after membrane uptake.P Restoration of intracellular ATP content helps preservation of cell viability during ischaemia and reperfusion.":" ATP also contributes to endothelium-dependent vasodilation during ischaemic events." Adenosine activities are mediated by the interaction with specific cell receptors, termed A 1 and A2 on the basis of the high (nM range) and low (J.LM range) affinity and the adenylate-cyclase inhibiting and stimulating properties, respectively." More recently, a third adenosine receptor has been characterized, termed A3, the location and function of which are still under study."
In addition to the effects mentioned above, which can be referred mainly to an interaction with A2 receptors, more recently a further activity has been described for adenosine in ischaemia via an A 1 47 and maybe A3 receptor" operating mechanism. In fact, adenosine is now presumed to be the major determinant of the so-calIed ischaemic preconditioning phenomenon.F:" Ischaemic preconditioning consists of brief periods of submaximal ischaemia that render the myocardium very resistant to subsequent critical ischaemia." Thus, pulse increases in adenosine plasma levels would account for a mechanism of protection towards ischaemia. First, ischaemic preconditioning was described for the rnyocardiumf'r" and evidence of the phenomenon derived from animal models,47-49 catheterization laboratories" and clinical observation of prodromal angina in humans." More recently, evidence has been supported that Vascuiar Medicine 1997; 2: 77-81 ischaemic preconditioning occurs also in the rat brain, 52 and maybe in the limbs of patients affected with intermittent claudication."
There is compelling evidence that regular submaximal exercise increases tissue resistance to the appearance of ischaemic changes for more intensive exercise.Y'" Circulatory changes induced by exercise, mainly those at the microcirculatory level, were considered as playing the pivotal role in inducing such clinical findings.P:" In our laboratory, it was shown that physical exercise induces marked metabolic changes leading to the appearance of lactic acidosis in extracellular fluids as well as a significant increase in plasma levels of adenosine and ATP." Carnitine infusion induces changes in plasma levels of purine derivatives similar to those observed in the biologic response to exercise. If adenosine is the actual mediator of ischaemic preconditioning, this phenomenon could be induced without provoking tissue ischaemia by the infusion of safe drugs such as carnitine derivatives. Such a possibility could represent a possible explanation for the anti-ischaemic activity of these drugs.
Because the effects of carnitine derivatives may be related to physiological mechanisms of tissue protection occurring during ischaemia, new pharmacologic perspectives for the compounds may arise. However, further studies are needed to support biologic and clinical evidence for the endogenous purine-mediated activity of carnitine derivati ves.
